Risk Factors for Glucose 6-Phosphate Dehydrogenase and COVID-19 Disease—A Retrospective Study at a Major Saudi Tertiary Center
Abstract
:1. Introduction
2. Method
3. Results
Comparison between COVID-19 Patients with and without G6PD
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Murray, K.; Rodwell, V.; Bender, D.; Botham, K.M.; Weil, P.A.; Kennelly, P.J. Harper’s Illustrated Biochemistry. 28; Citeseer: New York, NY, USA, 2009. [Google Scholar]
- Champe, P.C.; Harvey, R.A.; Ferrier, D.R. Biochemistry; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005. [Google Scholar]
- Harcke, S.J.; Rizzolo, D.; Harcke, H.T. G6PD deficiency: An update. Jaapa 2019, 32, 21–26. [Google Scholar] [CrossRef] [PubMed]
- Zhao, J.; Zhang, X.; Guan, T.; Wang, X.; Zhang, H.; Zeng, X.; Dai, Q.; Wang, Y.; Zhou, L.; Ma, X. The association between glucose-6-phosphate dehydrogenase deficiency and abnormal blood pressure among prepregnant reproductive-age Chinese females. Hypertens. Res. 2019, 42, 75–84. [Google Scholar] [CrossRef]
- Thomas, J.E.; Kang, S.; Wyatt, C.J.; Kim, F.S.; Mangelsdorff, A.D.; Weigel, F.K. Glucose-6-phosphate dehydrogenase deficiency is associated with cardiovascular disease in US military centers. Tex. Heart Inst. J. 2018, 45, 144–150. [Google Scholar] [CrossRef] [PubMed]
- Pes, G.M.; Parodi, G.; Dore, M.P. Glucose-6-phosphate dehydrogenase deficiency and risk of cardiovascular disease: A propensity score-matched study. Atherosclerosis 2019, 282, 148–153. [Google Scholar] [CrossRef] [PubMed]
- Frank, J.E. Diagnosis and management of G6PD deficiency. Am. Fam. Physician 2005, 72, 1277–1282. [Google Scholar]
- Reading, N.S.; Sirdah, M.M.; Shubair, M.E.; Nelson, B.E.; Al-Kahlout, M.S.; Al-Tayeb, J.M.; Aboud, L.N.; Shaban, M.A.; Luzzatto, L.; Prchal, J.T. Favism, the commonest form of severe hemolytic anemia in Palestinian children, varies in severity with three different variants of G6PD deficiency within the same community. Blood Cells Mol. Dis. 2016, 60, 58–64. [Google Scholar] [CrossRef]
- Luzzatto, L.; Mehta, A.; Vulliamy, T. Glucose-6-phosphate dehydrogenase deficiency. Metab. Mol. Bases Inherit. Dis. 1995, 8, 4517–4553. [Google Scholar]
- La Vieille, S.; Lefebvre, D.E.; Khalid, A.F.; Decan, M.R.; Godefroy, S. Dietary restrictions for people with glucose-6-phosphate dehydrogenase deficiency. Nutr. Rev. 2019, 77, 96–106. [Google Scholar] [CrossRef]
- Renard, D.; Rosselet, A. Drug-induced hemolytic anemia: Pharmacological aspects. Transfus. Clin. Et Biol. 2017, 24, 110–114. [Google Scholar] [CrossRef]
- Atzrodt, C.L.; Maknojia, I.; McCarthy, R.D.; Oldfield, T.M.; Po, J.; Ta, K.T.; Stepp, H.E.; Clements, T.P. A Guide to COVID-19: A global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020, 287, 3633–3650. [Google Scholar] [CrossRef]
- He, X.; Lau, E.H.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y.C.; Wong, J.Y.; Guan, Y.; Tan, X. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 2020, 26, 672–675. [Google Scholar] [CrossRef] [PubMed]
- Brooks, S.K.; Webster, R.K.; Smith, L.E.; Woodland, L.; Wessely, S.; Greenberg, N.; Rubin, G.J. The psychological impact of quarantine and how to reduce it: Rapid review of the evidence. Lancet 2020, 395, 912–920. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Wang, Y.; Chen, Y.; Qin, Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J. Med. Virol. 2020, 92, 568–576. [Google Scholar] [CrossRef] [PubMed]
- Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef]
- Morris, G.; Bortolasci, C.C.; Puri, B.K.; Olive, L.; Marx, W.; O’Neil, A.; Athan, E.; Carvalho, A.F.; Maes, M.; Walder, K. The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. Life Sci. 2020, 258, 118166. [Google Scholar]
- Jain, S.K.; Parsanathan, R.; Levine, S.N.; Bocchini, J.A.; Holick, M.F.; Vanchiere, J.A. The potential link between inherited G6PD deficiency, oxidative stress, and vitamin D deficiency and the racial inequities in mortality associated with COVID-19. Free Radic. Biol. Med. 2020, 161, 84–91. [Google Scholar] [CrossRef]
- Aydemir, D.; Ulusu, N.N. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths? Pathog. Glob. Health 2020, 114, 109–110. [Google Scholar] [CrossRef]
- Ulusu, N.N. Glucose-6-phosphate dehydrogenase deficiency and Alzheimer’s disease: Partners in crime? The hypothesis. Med. Hypotheses 2015, 85, 219–223. [Google Scholar] [CrossRef]
- Wu, Y.-H.; Tseng, C.-P.; Cheng, M.-L.; Ho, H.-Y.; Shih, S.-R.; Chiu, D.T.-Y. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. J. Infect. Dis. 2008, 197, 812–816. [Google Scholar] [CrossRef]
- Aydemir, D.; Hashemkhani, M.; Acar, H.Y.; Ulusu, N.N. In vitro interaction of glutathione S-transferase-pi enzyme with glutathione-coated silver sulfide quantum dots: A novel method for biodetection of glutathione S-transferase enzyme. Chem. Biol. Drug Des. 2019, 94, 2094–2102. [Google Scholar] [CrossRef]
- Elhabyan, A.; Elyaacoub, S.; Sanad, E.; Abukhadra, A.; Elhabyan, A.; Dinu, V. The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review. Virus Res. 2020, 289, 198163. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.-C.; Ma, T.-H.; Tjong, W.-Y.; Stern, A.; Chiu, D.T.-Y. G6PD deficiency, redox homeostasis, and viral infections: Implications for SARS-CoV-2 (COVID-19). Free Radic. Res. 2021, 55, 364–374. [Google Scholar] [CrossRef] [PubMed]
- Siddiqui, T.; Khan, A.H. Hepatitis A and cytomegalovirus infection precipitating acute hemolysis in glucose-6-phosphate dehydrogenase deficiency. Mil. Med. 1998, 163, 434–435. [Google Scholar] [CrossRef] [PubMed]
- Mushtaq, K.; Soliman, A.T.; Nashwan, A.J.; Iqbal, F.; Karawia, A.A.; Ahmed, D.H.; Hailan, Y.M.; Alawad, M.J.; Abubakar, M.; Gul, M.I. Hematologic Outcomes of COVID-19 Patients with and without G6PD Deficiency: A Comparative Study. Qatar Med. J. 2022, 2022, 54. [Google Scholar] [CrossRef]
- Aydemir, D.; Dağlıoğlu, G.; Candevir, A.; Kurtaran, B.; Bozdogan, S.T.; Inal, T.C.; Ulusu, N.N. COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients. Nucl. Nucl. Nucleic Acids 2021, 40, 505–517. [Google Scholar] [CrossRef]
- Lee, J.; Poitras, B.T. Prevalence of glucose-6-phosphate dehydrogenase deficiency, US Armed Forces, May 2004–September 2018. MSMR 2019, 26, 14–17. [Google Scholar]
- Howes, R.E.; Piel, F.B.; Patil, A.P.; Nyangiri, O.A.; Gething, P.W.; Dewi, M.; Hogg, M.M.; Battle, K.E.; Padilla, C.D.; Baird, J.K. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: A geostatistical model-based map. PLoS Med. 2012, 9, e1001339. [Google Scholar] [CrossRef]
- Ntyonga-Pono, M.-P. COVID-19 infection and oxidative stress: An under-explored approach for prevention and treatment? Pan Afr. Med. J. 2020, 35 (Suppl. S2), 12. [Google Scholar] [CrossRef]
- Zhang, Z.-L.; Hou, Y.-L.; Li, D.-T.; Li, F.-Z. Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand. J. Clin. Lab. Investig. 2020, 80, 441–447. [Google Scholar] [CrossRef]
- Jamerson, B.D.; Haryadi, T.H.; Bohannon, A. Glucose-6-phosphate dehydrogenase deficiency: An actionable risk factor for patients with COVID-19? Arch. Med. Res. 2020, 51, 743–744. [Google Scholar] [CrossRef]
- Vick, D.J. Evaluation of glucose-6-phosphate dehydrogenase (G6PD) status in US military and VA patients with COVID-19 infection. BMJ Mil Health 2021, 167, 144. [Google Scholar] [CrossRef] [PubMed]
Gender/Age | G6PD Group (233) Number/Percentage | G6PD Group + COVID-19 [21] Number/Percentage | COVID-19 (42,856) Number/Percentage |
---|---|---|---|
Male | 176/75.5% | 14/66.6 | 20,647/48.17 |
Female | 57/24.4 | 7/33.33 | 22,206/51.81 |
UNKNWON | NA | NA | 2/0.004 |
<15 | 134/57.5 | 11/52.38 | 5559/12.97 |
>15 <30 | 35/15.02 | 3/14.28 | 11,413/26.663 |
>30 <50 | 32/13.7 | 4/19.04 | 15,507/36.18 |
>50 <80 | 22/9.4 | 3/14.28 | 10,860/25.34 |
>80 | NA | NA | 41/0.095 |
G6PD Group (233) Number/Percentage | G6PD Group + COVID-19 [21] Number/Percentage | COVID-19 (42,856) Number/Percentage | |
---|---|---|---|
PT | 50/21.46 | 11/52.38 | 8375/19.54 |
PTT | 46/19.64 | 10/47.62 | 191/0.45 |
D-DIMER | 20/8.58 | 7/33.33 | 20,815/48.57 |
Fibrinogen | 12/5.15 | 4/19.05 | 1585/3.70 |
LHD | 74/31.76 | 13/61.90 | 826/1.93 |
Total bilirubin | 141/60.52 | 16/76.19 | 290/0.68 |
Ferritin | 95/40.77 | 11/52.38 | 921/2.15 |
AST | 138/59.23 | 16/76.19 | 524/1.22 |
ALT | 112/48.07 | 14/66.67 | 363/0.85 |
Creatinine | 162/69.53 | 18/85.71 | 1955/4.56 |
Blood Urea Nitrogen (BUN) | 159/68.24 | 18/85.71 | 204/0.48 |
Blood Glucose Test | 151/64.81 | 17/80.95 | 278/0.65 |
C-Reactive Protein (CRP) | 68/29.18 | 10/47.62 | 807/1.8 |
G6PD | G6PD + COVID-19 | COVID-19 | ||||
---|---|---|---|---|---|---|
Mean | Std. Deviation | Mean | Std. Deviation | Mean | Std. Deviation | |
PT second | 11.55 | 1.25 | 11.43 | 1.31 | 11.47 | 3.56 |
PTT second | 27.73 | 3.26 | 26.35 | 2.08 | 28.31 | 4.55 |
D-DIMER mg/L | 2.07 | 2.46 | 2.95 | 3.52 | 1.92 | 3.66 |
Fibrinogen gm/L | 3.26 | 1.39 | 3.33 | 1.92 | 4.49 | 1.98 |
LHD U/L | 466.07 | 462.34 | 614.77 | 516.32 | 321.70 | 221.56 |
Tbili μmol/L | 27.51 | 36.26 | 21.94 | 23.63 | 9.66 | 5.34 |
Feeritin ug/L | 565.91 | 1811.98 | 1977.11 | 4570.85 | 545.53 | 1660.98 |
AST U/L | 32.56 | 36.23 | 39.56 | 34.75 | 31.29 | 37.12 |
ALT U/L | 29.69 | 44.28 | 34.21 | 34.39 | 28.99 | 40.01 |
Albumin g/L | 42.43 | 4.60 | 37.85 | 6.28 | 40.68 | 5.10 |
Creatinin μmol/L | 63.94 | 60.16 | 74.67 | 69.34 | 125.61 | 175.73 |
BUN mmol/L | 4.27 | 3.24 | 6.17 | 8.65 | 5.71 | 4.01 |
GLU Random | 5.46 | 2.49 | 6.08 | 2.63 | 6.16 | 2.78 |
CRP mg/L | 35.71 | 53.97 | 25.32 | 50.47 | 50.39 | 78.75 |
Group | G6PD | G6PD + COVID-19 | COVID-19 | ||||
---|---|---|---|---|---|---|---|
Std. Test Statistic | p Value | Std. Test Statistic | p Value | Std. Test Statistic | p Value | ||
PT | G6PD | - | - | 0.644 | 0.519 | 2.736 | 0.006 |
G6PD + COVID-19 | - | - | 0.575 | 0.565 | |||
COVID-19 | - | - | |||||
D-DIMER | G6PD | - | - | −0.220 | 0.826 | 2.029 | 0.042 |
G6PD + COVID-19 | - | - | 1.457 | 0.145 | |||
COVID-19 | - | - | |||||
Fibrinogen | G6PD | - | - | −0.086 | 0.932 | −2.218 | 0.027 |
G6PD + COVID-19 | - | - | −1.185 | 0.236 | |||
COVID-19 | - | - | |||||
LHD | G6PD | - | - | −1.890 | 0.059 | 1.190 | 0.234 |
G6PD + COVID-19 | - | - | 2.550 | 0.011 | |||
COVID-19 | - | - | |||||
Tbili | G6PD | - | - | 0.515 | 0.607 | 6.670 | <0.001 |
G6PD + COVID-19 | - | - | 2.138 | 0.033 | |||
COVID-19 | - | - | |||||
Feeritin | G6PD | - | - | −2.490 | 0.013 | −2.483 | 0.013 |
G6PD + COVID-19 | - | - | 1.733 | 0.083 | |||
COVID-19 | - | - | |||||
AST | G6PD | - | - | −1.421 | 0.155 | 2.599 | 0.009 |
G6PD + COVID-19 | - | - | 2.458 | 0.014 | |||
COVID-19 | - | - | |||||
ALT | G6PD | - | - | −1.540 | 0.124 | −2.533 | 0.011 |
G6PD + COVID-19 | - | - | 0.597 | 0.550 | |||
COVID-19 | - | - | |||||
Creatinin | G6PD | - | - | −0.324 | 0.746 | −8.657 | 0.000 |
G6PD + COVID-19 | - | - | −2.649 | 0.008 | |||
COVID-19 | - | - | |||||
BUN | G6PD | - | - | −0.803 | 0.422 | −4.317 | <0.001 |
G6PD + COVID-19 | - | - | −1.045 | 0.296 | |||
COVID-19 | - | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alotaibi, B.A.; Aldali, J.A.; Aldali, H.J.; Alasiri, G.A.; Elsokkary, E.M.; Al Mugairi, A.; Almuqrin, A.M. Risk Factors for Glucose 6-Phosphate Dehydrogenase and COVID-19 Disease—A Retrospective Study at a Major Saudi Tertiary Center. Viruses 2023, 15, 1224. https://doi.org/10.3390/v15061224
Alotaibi BA, Aldali JA, Aldali HJ, Alasiri GA, Elsokkary EM, Al Mugairi A, Almuqrin AM. Risk Factors for Glucose 6-Phosphate Dehydrogenase and COVID-19 Disease—A Retrospective Study at a Major Saudi Tertiary Center. Viruses. 2023; 15(6):1224. https://doi.org/10.3390/v15061224
Chicago/Turabian StyleAlotaibi, Badi A., Jehad A. Aldali, Hamzah J. Aldali, Glowi A. Alasiri, Emadeldin M. Elsokkary, Areej Al Mugairi, and Abdulaziz M. Almuqrin. 2023. "Risk Factors for Glucose 6-Phosphate Dehydrogenase and COVID-19 Disease—A Retrospective Study at a Major Saudi Tertiary Center" Viruses 15, no. 6: 1224. https://doi.org/10.3390/v15061224
APA StyleAlotaibi, B. A., Aldali, J. A., Aldali, H. J., Alasiri, G. A., Elsokkary, E. M., Al Mugairi, A., & Almuqrin, A. M. (2023). Risk Factors for Glucose 6-Phosphate Dehydrogenase and COVID-19 Disease—A Retrospective Study at a Major Saudi Tertiary Center. Viruses, 15(6), 1224. https://doi.org/10.3390/v15061224